Talzenna
Pfizer Joins Prostate Cancer PARP Showdown: A Three-Way Battle for Breakthrough Treatment
SG Tylor
Pfizer expects that the FDA’s approval of Talzenna, a PARP inhibitor, for castration-resistant prostate cancer (CRPC) would enable it to ...
